| Page 1989 | Kisaco Research
 

attended last year

attended last year

attended last year

 

at London 2017

at London 2017

at London 2017

 

From London 2017

From London 2017

From London 2017

 

Dr. Niels Schaft

Universitätsklinikum Erlangen

Dr. Niels Schaft

Universitätsklinikum Erlangen

Dr. Niels Schaft

Universitätsklinikum Erlangen
 
3D Cell Models Congress
24-25 Jan 2018
Berlin, Germany
The 3D Cell Models Congress 2018 will present the latest developments and innovation in three-dimensional cell models including organoids, spheroids, and organ-on-a-chip, as well as bioprinting technologies.
 

Dr Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Career

present

Chief Scientific Officer at Cellex Patient Treatment GmbH

2013 - 2014

 

Post-Doc., Institute of Radiopharmaceutical Cancer Research Dep. Radioimmunology, Helmholtz Zentrum Dresden Rossendorf, Germany

2005 - 2013

Post-Doc., Institute of Immunology, TU Dresden, Germany

 

Education

2000 - 2005

Dr Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Dr Marc Cartellieri

Chief Scientific Officer
Cellex Patient Treatment

Career

present

Chief Scientific Officer at Cellex Patient Treatment GmbH

2013 - 2014

 

Post-Doc., Institute of Radiopharmaceutical Cancer Research Dep. Radioimmunology, Helmholtz Zentrum Dresden Rossendorf, Germany

2005 - 2013

Post-Doc., Institute of Immunology, TU Dresden, Germany

 

Education

2000 - 2005

Doctoral Thesis (PhD): “Untersuchungen zum Gag- und Pol-Protein des Prototypischen Foamyvirus (PFV)“, Institute of Virology, TU Dresden, Germany

1993 - 2000

Master of Science (Biology), Ernst-Moritz-Arndt-Universität Greifswald, Germany

 

Gareth Thomas

University of Southampton

Gareth Thomas

University of Southampton

Gareth Thomas

University of Southampton
 

Dr Stephen Miller

Director
Interdepartmental Immunobiology Center

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago.  He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center.  Dr.

Dr Stephen Miller

Director
Interdepartmental Immunobiology Center

Dr Stephen Miller

Director
Interdepartmental Immunobiology Center

Dr. Stephen Miller is the Judy E. Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine in Chicago.  He received his Ph.D. in 1975 from the Pennsylvania State University and did postdoctoral training at the University of Colorado Health Sciences Center before joining the faculty at Northwestern in 1981 where he currently serves as Director of the Northwestern University Interdepartmental Immunobiology Center.  Dr. Miller is internationally recognized for his research on pathogenesis and regulation of autoimmune diseases.  He has published over 360 journal articles, reviews and book chapters and has trained multiple generations of scientists. His work has significantly enhanced understanding of immune inflammatory processes underlying chronic autoimmune disease employing animal models of multiple sclerosis (MS) and Type 1 diabetes (T1D).  His work has focused on the study of the cellular and molecular mechanisms underlying treatment of established T cell-mediated autoimmune diseases using antigen-specific immune tolerance.  His current work is is geared to translating the use of antigen-linked biodegradable PLG nanoparticles for the treatment of human immune-mediated diseases including autoimmunity, allergy and tissue/organ transplantation.

 

Judy Gugenheim

Research Professor of Microbiology-Immunology
Northwestern Medical School

Judy Gugenheim

Research Professor of Microbiology-Immunology
Northwestern Medical School

Judy Gugenheim

Research Professor of Microbiology-Immunology
Northwestern Medical School
 

Dr Giovanna Lombardi

Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation
Kings College London

Giovanna Lombardi is Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, at King’s College London (since 2005). From 1987 to 2005 she was based at the Department of Immunology at the Hammersmith Hospital and before that at the University of Rome, Italy.

Dr Giovanna Lombardi

Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation
Kings College London

Dr Giovanna Lombardi

Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation
Kings College London

Giovanna Lombardi is Professor of Human Transplant Immunology in the Division of Transplantation Immunology and Mucosal Biology, MRC Centre for Transplantation, at King’s College London (since 2005). From 1987 to 2005 she was based at the Department of Immunology at the Hammersmith Hospital and before that at the University of Rome, Italy.

Her research has focused on the mechanisms of transplant rejection and tolerance as well as on the phenotype and function of regulatory T cells (Tregs) in health and disease, both in the murine system and in man. Recently her laboratory has established a clinical protocol to expand Tregs in vitro. Tregs has been used in two clinical trials in renal transplant patients as part of a large EU cell therapy consortium and in liver transplant patients supported by the MRC. In parallel, her group has demonstrated that adoptive cell therapy using alloantigen-specific regulatory T cells can offer an advantage compared to polyclonal Tregs for preventing chronic allograft rejection. A GMP compatible cell sorter to generate highly pure Tregs is under validation and this approach will open the possibility of using alloantigen-specific Tregs for future clinical trials within the next few years.